Peptilogics Market Research Report
Company Overview
Name: Peptilogics
Mission: To revolutionize the discovery process for novel peptide therapeutics to help patients with serious and life-threatening diseases.
Founded: 2013
Founder: Jonathan Steckbeck, PhD, MBA
Key People:
- Jonathan Steckbeck, PhD, MBA - CEO & Founder
- Atul Deshpande, PhD, MBA, A-PMP - Chief Strategy Officer
- Albert Fonticiella, MBA, SHRM-SCP - VP of People
- Steve Kulp - SVP, Corporate Operations
- Nicholas Nystrom, PhD - Chief Technology Officer
- Nick Pachuda, DPM - Chief Operating Officer
- Dietrich Stephan, PhD - Chairman of the Board
Headquarters: No information available
Number of Employees: No information available
Revenue: No information available
Known For:
Peptilogics is known for exploring untapped chemical space to engineer peptides to treat some of the most challenging diseases. They utilize a blend of artificial intelligence (AI) and peptide research & development (R&D) to design peptides with optimized binding, selectivity, safety, and other drug candidate properties.
Products
PLG0206
Description: PLG0206 is an investigational, broad-spectrum orthopedic anti-infective peptide for the treatment of periprosthetic joint infection (PJI). It is currently being evaluated in clinical trials.
Key Features:
- Rapid-acting and bactericidal
- Unique mechanism of action disrupting bacterial cell membranes
- Targets bacteria and persistent pathogens that produce biofilm, evading conventional antibiotics
- Orphan Drug Designation and Qualified Infectious Disease Product (QIDP) status by the FDA
- Demonstrated potent in vitro and nonclinical activity, acceptable safety profile in Phase 1 study
Pipeline Programs
Discovery Programs:
- PLGAI002: Rare Genetic Disease (Discovery Phase)
- PLGAI003: Oncology (Discovery Phase)
- PLGAI004: Oncology (Discovery Phase)
Development Programs:
- PLG0206: Prosthetic Joint Infection (Phase 1)
- PLG0206: Orthopedic Expansion (Preclinical)
- PLG0301: Cystic Fibrosis Infection and Inflammation (Preclinical)
Recent Developments
New Products Launched:
- PLG0206 is undergoing clinical trials for the treatment of periprosthetic joint infection.
New Features Added:
- No information available.
New Partnerships:
- Epiaxis Therapeutics & Peptilogics: Entered a strategic drug discovery partnership (August 10, 2022)
- Orion Biotechnology & Peptilogics: Strategic research collaboration to enable AI-driven drug discovery against undrugged GPCR target (July 12, 2022)
- Peptilogics & Cerebras Systems: Partnership on AI solutions to advance the future of peptide therapeutics (August 2021)
Press Releases:
- September 19, 2023: Peptilogics reports positive 180-day top-line interim data from Phase 1b trial of PLG0206 in patients with PJI.
- May 24, 2023: Reports positive 90-day top-line interim data from Phase 1b trial of PLG0206 in patients with PJI.
- April 6, 2023: Completes Phase 1b trial enrollment and will present interim top-line safety and tolerability data of PLG0206.
- October 20, 2022: Presenting data at IDWeek 2022 on PLG0206 targeting bacteria causing PJI.
- October 7, 2022: Presents data at 2022 ASM/ESCMID joint conference on antimicrobial resistance.
Publications:
- September 2022: Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class (PLOS One).
- January 2022: A Phase 1 study of safety, tolerability and pharmacokinetics of single ascending doses of PLG0206 (Antimicrobial Agents and Chemotherapy).
- November 2021: Prospective activity of PLG0206 on chronic PJI total knee arthroplasty components (Microbiology Spectrum).
- December 2021: Engineered antibiotic peptide PLG0206 eliminates biofilms and is a potential treatment for PJI (Antibiotics).
Presentations:
- 2022 IDWeek: Presented multiple posters on antimicrobial activity of PLG0206 against various bacterial pathogens.
- AAOS 2022: Presented data on potential treatment capabilities of PLG0206 for PJI.
- ECCMID 2022: Presented on resistance development and broad-spectrum activity of PLG0206.
This report is based on the data provided, and no additional commentary is included.
